Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRXNASDAQ:GANXNASDAQ:MBRXNASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$0.87-15.9%$1.27$0.78▼$41.50$37.64M1.211.09 million shs1.72 million shsGANXGain Therapeutics$1.77-1.1%$1.87$0.89▼$3.19$53.60M0.11297,802 shs779,231 shsMBRXMoleculin Biotech$0.27-54.2%$0.88$0.25▼$4.71$8.24M1.561.61 million shs16.49 million shsMDCXMedicus Pharma$2.49-3.5%$4.24$1.80▼$8.94$35.02MN/A398,361 shs181,418 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals-15.87%-19.02%-33.35%-51.05%+86,649,900.00%GANXGain Therapeutics-1.12%+2.31%-2.21%-24.36%+38.28%MBRXMoleculin Biotech-53.97%-58.41%-72.47%-75.50%-93.29%MDCXMedicus Pharma-3.49%-4.23%-67.70%-25.00%+248,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals0.2809 of 5 stars0.03.00.00.02.40.00.0GANXGain Therapeutics2.5182 of 5 stars3.63.00.00.03.20.00.6MBRXMoleculin Biotech3.118 of 5 stars3.55.00.00.02.50.01.3MDCXMedicus Pharma1.5962 of 5 stars3.80.00.00.01.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AGANXGain Therapeutics 3.17Buy$8.20363.28% UpsideMBRXMoleculin Biotech 3.00Buy$4.001,398.13% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50843.78% UpsideCurrent Analyst Ratings BreakdownLatest MBRX, BDRX, GANX, and MDCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.006/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K67.37N/AN/A$0.29 per share2.99GANXGain Therapeutics$50K1,060.23N/AN/A$0.28 per share6.32MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/A7/11/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%6/27/2025 (Estimated)Latest MBRX, BDRX, GANX, and MDCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/A3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.011.751.75GANXGain Therapeutics0.052.222.22MBRXMoleculin BiotechN/A1.351.35MDCXMedicus PharmaN/A1.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%GANXGain Therapeutics11.97%MBRXMoleculin Biotech15.52%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%GANXGain Therapeutics7.18%MBRXMoleculin Biotech1.90%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableGANXGain Therapeutics2029.95 million27.80 millionOptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableMDCXMedicus PharmaN/A13.57 millionN/AN/AMBRX, BDRX, GANX, and MDCX HeadlinesRecent News About These CompaniesMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma to Present at Bio Convention and Expand Cancer Treatment PortfolioJune 12, 2025 | tipranks.comMedicus Pharma Ltd. to Present at 2025 Bio International ConventionJune 12, 2025 | newsfilecorp.comMedicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horsesJune 9, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug ...June 9, 2025 | gurufocus.comMedicus Pharma Submits FDA Plan for Novel Equine Cancer TreatmentJune 9, 2025 | tipranks.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in HorsesJune 9, 2025 | newsfilecorp.comMedicus Pharma appoints KPMG as new auditor, expands global clinical programsJune 6, 2025 | proactiveinvestors.comMedicus Pharma completes $7 million public offeringJune 4, 2025 | uk.investing.comMedicus Pharma Ltd. Announces Closing of $7.0 Million Public OfferingJune 2, 2025 | newsfilecorp.comMedicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street ZenMay 31, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)May 30, 2025 | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30, 2025 | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30, 2025 | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29, 2025 | gurufocus.comMedicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment TrialsMay 29, 2025 | tipranks.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public OfferingMay 29, 2025 | newsfilecorp.comMDCX Medicus Pharma Ltd.May 29, 2025 | seekingalpha.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, BDRX, GANX, and MDCX Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$0.87 -0.16 (-15.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.40%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Gain Therapeutics NASDAQ:GANX$1.77 -0.02 (-1.12%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.92 +0.15 (+8.47%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Moleculin Biotech NASDAQ:MBRX$0.27 -0.32 (-54.20%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.12%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Medicus Pharma NASDAQ:MDCX$2.49 -0.09 (-3.49%) As of 06/20/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
